Recent Advances in GLP-1 Receptor Agonists for Type 2 Diabetes: 2025 Updates for PLAB 2

Introduction

GLP-1 receptor agonists (GLP-1 RAs) have revolutionized the management of type 2 diabetes mellitus (T2DM) in recent years. As we progress through 2025, these agents continue to demonstrate remarkable cardiovascular benefits, weight loss efficacy, and emerging therapeutic applications. For PLAB 2 candidates, understanding these recent advances is crucial, as they represent some of the most significant developments in diabetes care that are increasingly tested in clinical scenarios.

Mechanism of Action: Quick Recap

GLP-1 receptor agonists work by mimicking the action of endogenous glucagon-like peptide-1, which:

• Enhances glucose-dependent insulin secretion

• Suppresses glucagon secretion

• Delays gastric emptying

• Promotes satiety and reduces appetite

Key Recent Advances (2024-2025)

1. Cardiovascular Outcomes Trial Updates

The LEADER and SUSTAIN-6 trials have established cardiovascular benefits for liraglutide and semaglutide respectively. Recent 2024-2025 analyses have further clarified:

• Reduced MACE outcomes: Major adverse cardiovascular events reduction of 15-26% in high-risk T2DM patients

• Heart failure benefits: Emerging data shows reduction in hospitalization for heart failure

• Renal protection: Continued evidence of slowing diabetic kidney disease progression

2. Dual and Triple Agonists

The development of multi-agonist therapies has been a major breakthrough:

3. Oral Semaglutide Expansion

The availability of oral semaglutide has increased, with:

• New dosing regimens approved

• Better gastrointestinal tolerance profiles

• Expanded indications for cardiovascular risk reduction

4. Emerging Non-Diabetic Applications

GLP-1 RAs are now being studied for:

• Obesity management (without diabetes)

• NASH/NAFLD treatment

• Alzheimer's disease prevention

• Polycystic ovary syndrome (PCOS)

PLAB 2 Clinical Scenario Implications

Prescribing Considerations

When managing T2DM patients in PLAB 2 stations, consider:

1. First-line after metformin: For patients with atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD)

2. Weight management: Particularly valuable for obese/overweight patients

3. Injection techniques: Ensure proper teaching of subcutaneous administration

Key Side Effects to Counsel Patients About

• Gastrointestinal: Nausea, vomiting, diarrhea (usually transient)

• Pancreatitis risk: Caution in patients with history

• Thyroid C-cell tumors: Contraindicated in MEN 2 or family history

Drug Interactions

• May affect absorption of oral medications

• Requires dose adjustment of insulin secretagogues

Guidelines Update 2025

The ADA/EASD Consensus Report 2024-2025 now recommends:

"GLP-1 receptor agonists with proven cardiovascular benefit are recommended as first-line injectable therapy in patients with T2DM and ASCVD, HF, or CKD"

This represents a significant shift from earlier approaches and is likely to be tested in PLAB 2.

Summary for PLAB 2 Success

Remember these key points:

• ✅ GLP-1 RAs provide cardiovascular, renal, and weight benefits

• ✅ Consider for patients with ASCVD, HF, or obesity

• ✅ Monitor for GI side effects

• ✅ Counsel on injection technique

• ✅ Be aware of contraindications (thyroid cancer, pancreatitis)

• ✅ Dual agonists like tirzepatide showing superior efficacy

Conclusion

The landscape of type 2 diabetes management has been transformed by GLP-1 receptor agonists. For PLAB 2 candidates, understanding these agents' mechanisms, benefits, and practical prescribing considerations is essential. The 2025 updates emphasize their role not just in glycemic control but as agents with profound cardiovascular and metabolic benefits. Stay updated with these advances as they continue to shape modern diabetes care.

Good luck with your PLAB 2 preparation!